Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17492160 | 0.93 | PPARA (0.50) | PPARAPPARGSCN9AITGB3ITGA2B | |
| SCHEMBL17492162 | 0.93 | PPARA (0.50) | PPARAPPARGSCN9AITGB3ITGA2B | |
| SCHEMBL16384487 | 0.83 | PPARA (0.58) | PPARAPPARGITGB3ITGA2BACE | |
| SCHEMBL17492077 | 0.82 | SCN9A (0.46) | PPARAPPARGSCN9AITGB3ITGA2B | |
| SCHEMBL17492075 | 0.82 | SCN9A (0.46) | PPARAPPARGSCN9AITGB3ITGA2B | |
| SCHEMBL14134838 | 0.80 | PPARA (0.52) | PPARAPPARGSCN9AITGB3ITGA2B | |
| SCHEMBL17491974 | 0.78 | GRN (0.54) | PPARAPPARGITGB3ITGA2BACE | |
| SCHEMBL17491971 | 0.78 | GRN (0.54) | PPARAPPARGITGB3ITGA2BACE | |
| SCHEMBL4024742 | 0.77 | PPARA (0.63) | PPARAPPARGACECTSS | |
| SCHEMBL4818304 | 0.76 | PPARA (0.62) | PPARAPPARGSCN9AITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873695-B2 | Serine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | PPARA 911/4885PPARG 345/4885SCN9A 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.